NextCure, Inc. (NASDAQ:NXTC) Sees Large Increase in Short Interest

Posted by Francis Steltz on Jul 25th, 2026

NextCure, Inc. (NASDAQ:NXTC – Get Free Report) was the recipient of a large increase in short interest in the month of July. As of July 15th, there was short interest totaling 1,323,834 shares, an increase of 734.7% from the June 30th total of 158,592 shares. Based on an average daily volume of 11,134,379 shares, the days-to-cover ratio is presently 0.1 days. Currently, 41.6% of the shares of the company are sold short.

NextCure Stock Performance

NXTC opened at $4.24 on Friday. The company has a fifty day moving average price of $3.91 and a two-hundred day moving average price of $8.98. NextCure has a 52 week low of $1.55 and a 52 week high of $15.74. The firm has a market capitalization of $15.31 million, a PE ratio of -0.25 and a beta of 1.42.

NextCure (NASDAQ:NXTC – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($1.87) EPS for the quarter, beating the consensus estimate of ($2.10) by $0.23. Equities analysts forecast that NextCure will post -7.89 EPS for the current year.

Institutional Investors Weigh In On NextCure

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NXTC. Marshall Wace LLP bought a new stake in NextCure in the fourth quarter valued at about $160,000. Millennium Management LLC bought a new position in NextCure during the fourth quarter worth about $185,000. Geode Capital Management LLC boosted its holdings in NextCure by 18.6% during the fourth quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after buying an additional 3,636 shares during the last quarter. Cable Car Capital LP grew its position in shares of NextCure by 13.1% during the 2nd quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock worth $349,000 after buying an additional 88,040 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of NextCure by 18.7% during the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock worth $477,000 after buying an additional 5,300 shares during the period. Institutional investors own 42.65% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on NXTC shares. Weiss Ratings downgraded NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 7th. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of NextCure in a report on Wednesday, July 15th. Wall Street Zen downgraded shares of NextCure from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Finally, Zacks Research upgraded NextCure from a “strong sell” rating to a “hold” rating in a research report on Thursday, June 11th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $19.00.

Read Our Latest Stock Report on NextCure

About NextCure

(Get Free Report)

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.